Elias Papatheodorou is a seasoned biotechnology executive with 30 years of work experience. He was the CEO of Swiss/French clinical stage fibrosis company Genkyotex ($GKTX.PA, acquired by Calliditas $CALT). Prior to Genkyotex, he was CBO of Swiss bispecific antibody biotechnology company Covagen (acquired by Janssen), SVP of Munich based Medigene (MDG1) and CEO of German biotechnology company Novosom AG (acquired by Marina Biotech).
 
He has served as Chair of Board of Memo Therapeutics (Zurich) and Heparegenix (Tubingen). Currently he sits on the Board of Scandinavian Tribune Therapeutics. Mr. Papatheodorou started his career from Philip Morris International and The Coca-Cola Company. He studied in the United States at Ithaca College and Cornell University.